Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014–2016: A cross-sectional study

1. Evans DK, Goldstein M, Popova A (2015) Health-care worker mortality and the legacy of the Ebola epidemic. Lancet Glob Health 3: e439–e440. doi: 10.1016/S2214-109X(15)00065-0 26163833

2. World Health Organization (2016) WHO global health workforce statistics. Geneva: World Health Organization. http://www.who.int/hrh/statistics/hwfstats/. Accessed 21 September 2016.

3. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, et al. (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371: 2092–2100. doi: 10.1056/NEJMoa1411680 25353969

4. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, et al. (2015) Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372: 40–47. doi: 10.1056/NEJMoa1411249 25372658

5. Qin E, Bi J, Zhao M, Wang Y, Guo T, et al. (2015) Clinical features of patients with Ebola virus disease in Sierra Leone. Clin Infect Dis 61: 491–495. doi: 10.1093/cid/civ319 25995207

6. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, et al. (2015) Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 15: 1292–1299. doi: 10.1016/S1473-3099(15)00144-9 26271406

7. Camacho A, Kucharski A, Aki-Sawyerr Y, White MA, Flasche S, et al. (2015) Temporal changes in Ebola transmission in Sierra Leone and implications for control requirements: a real-time modelling study. PLoS Curr 7.

8. Uyeki TM, Mehta AK, Davey RT Jr, Liddell AM, Wolf T, et al. (2016) Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 374: 636–646. doi: 10.1056/NEJMoa1504874 26886522

9. World Health Organization (2016) Emergency medical teams and World Health Organization. Geneva: World Health Organization. http://www.who.int/hac/techguidance/preparedness/foreign_medical_teams/en/. Accessed 21 September 2016.

10. Centers for Disease Control and Prevention (2016) Ebola (Ebola virus disease): CDC’s role. Atlanta: Centers for Disease Control and Prevention. http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/what-cdc-is-doing.html. Accessed 21 September 2016.

11. Clark D V, Kibuuka H, Millard M, Wakabi S, Lukwago L, et al. (2015) Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 15: 905–912. doi: 10.1016/S1473-3099(15)70152-0 25910637

12. Bertherat E, Renaut A, Nabias R, Dubreuil G, Georges-Courbot MC (1999) Leptospirosis and Ebola virus infection in five gold-panning villages in northeastern Gabon. Am J Trop Med Hyg 60: 610–615. 10348236

13. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe‐Tamfum JJ, et al. (1999) Clinical, virologic, and immunologic follow‐up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis 179: S28–S35. doi: 10.1086/514318 9988162

14. Leroy E, Baize S, Volchkov V, Fisher-Hoch S, Georges-Courbot M-C, et al. (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210–2215. 10881895

15. Johnson KM, Breman JG, Burke J, Declerq R, Ghysebrechts G, et al. (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56: 271–293. 307456

16. Bower H, Glynn J (2016) A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection. Sci Data. 4:160133.

17. Glynn J, Bower H, Johnson S, Houlihan C, Montesano C, et al. (2017) Asymptomatic infection and unrecognised Ebola virus disease: prevalence of Ebola virus sero-positivity in a large cross-sectional survey in Ebola-affected households, Sierra Leone, using a new non-invasive assay. Lancet Infect Dis. E-pub ahead of print.

18. Dean NE, Halloran ME, Yang Y, Longini IM (2016) Transmissibility and pathogenicity of Ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin Infect Dis 62: 1277–1286. doi: 10.1093/cid/ciw114 26932131

19. Richardson ET, Kelly JD, Barrie MB, Mesman AW, Karku S, et al. (2016) Minimally symptomatic infection in an Ebola “hotspot”: a cross-sectional serosurvey. PLoS Negl Trop Dis 10: e0005087. doi: 10.1371/journal.pntd.0005087 27846221

20. Biernacki P, Waldorf D (1981) Snowball sampling: problems and techniques of chain referral sampling. Sociol Methods Res 10: 141–163.

21. Lambe T, Rampling T, Samuel D, Bowyer G, Ewer K, et al. (2016) Detection of vaccine induced antibodies to Ebola virus in oral fluid. Open Forum Infect Dis 3: ofw031. doi: 10.1093/ofid/ofw031 27004234

22. Frey A, Di Canzio J, Zurakowski D (1998) A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35–41. 9894896

23. Trombley AR, Wachter L, Garrison J, Buckley-Beason VA, Jahrling J, et al. (2010) Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg 82: 954–960. doi: 10.4269/ajtmh.2010.09-0636 20439981

24. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, et al. (2016) A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 374: 1635–1646. doi: 10.1056/NEJMoa1411627 25629663

25. Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, et al. (2015) Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis 15: 1300–1304. doi: 10.1016/S1473-3099(15)00228-5 26321189

26. Fierz W (2004) Basic problems of serological laboratory diagnosis. Methods Mol Med 94: 393–427. 14959841

27. Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, et al. (2016) Antibody therapeutics for Ebola virus disease. Curr Opin Virol 17: 45–49. doi: 10.1016/j.coviro.2016.01.006 26826442

28. Bausch DG (2016) Sequelae after Ebola virus disease: even when it’s over it’s not over. Lancet Infect Dis 15: 865–866.

29. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, et al. (2014) Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20: 1126–1129. doi: 10.1038/nm.3702 25194571

30. Natesan M, Jensen SM, Keasey SL, Kamata T, Kuehne AI, et al. (2016) Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clin Vaccine Immunol 23: 717–724. doi: 10.1128/CVI.00107-16 27335383

31. Morris M, Cohen B, Andrews N, Brown D (2002) Stability of total and rubella-specific IgG in oral fluid samples: the effect of time and temperature. J Immunol Methods 266: 111–116. 12133627

32. Sealy TK, Erickson BR, Taboy C, Stroher U, Towner JS, et al. (2016) Laboratory response to Ebola—West Africa and United States. Morb Mortal Wkly Rep 65: 44–49.

33. Crowe SJ, Maenner MJ, Kuah S, Erickson BR, Coffee M, et al. (2016) Prognostic indicators for Ebola patient survival. Emerg Infect Dis 22: 217–223. doi: 10.3201/eid2202.151250 26812579

34. Rosello A, Mossoko M, Flasche S, Van Hoek AJ, Mbala P, et al. (2015) Ebola virus disease in the Democratic Republic of the Congo, 1976–2014. Elife 4: e09015. doi: 10.7554/eLife.09015 26525597

35. Arkell P, Youkee D, Brown CS, Kamara A, Kamara TB, et al. (2017) Quantifying the risk of nosocomial infection within Ebola Holding Units: a retrospective cohort study of negative patients discharged from five Ebola Holding Units in Western Area, Sierra Leone. Trop Med Int Heal 22: 32–40.

36. Public Health England (2016) Ebola virus disease, activity summary. Monthly summary 14: 07/01/2016. London: Public Health England. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/492221/Ebola_Activity_Summary_07_01_16.pdf. Accessed 12 April 2017.

37. Virtanen A, Nieminen P, Luostarinen T, Anttila A (2011) Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 20: 1960–1969. doi: 10.1158/1055-9965.EPI-11-0307 21752985

38. Olu O, Kargbo B, Kamara S, Wurie AH, Amone J, et al. (2015) Epidemiology of Ebola virus disease transmission among health care workers in Sierra Leone, May to December 2014: a retrospective descriptive study. BMC Infect Dis 15: 416. doi: 10.1186/s12879-015-1166-7 26464285

39. Bower H, Johnson S, Bangura MS, Kamara AJ, Kamara O, et al. (2016) Attack rates for Ebola virus disease in Ebola-affected households, Sierra Leone. Emerg Infect Dis 22: 1403–1411. doi: 10.3201/eid2208.160163 27144428

40. Biava M, Caglioti C, Bordi L, Castilletti C, Colavita F, et al. (2017) Detection of viral RNA in tissues following plasma clearance from an Ebola virus infected patient. PLOS Pathog 13: e1006065. doi: 10.1371/journal.ppat.1006065 28056096

41. Roels TH, Bloom AS, Buffington J, Muhungu GL, Mac Kenzie WR, et al. (1999) Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. J Infect Dis 179: S92–S97. doi: 10.1086/514286 9988170

42. Ebola nurse Pauline Cafferkey accused of concealing high temperature (2016). Nurs Stand 30: 8.

43. Gnambs T, Kaspar K (2015) Disclosure of sensitive behaviors across self-administered survey modes: a meta-analysis. Behav Res Methods 47: 1237–1259. doi: 10.3758/s13428-014-0533-4 25410404